JOP20200118A1 - مدرات الافراز مشتقة من اوكسالوباكتير فورميجينيس - Google Patents

مدرات الافراز مشتقة من اوكسالوباكتير فورميجينيس

Info

Publication number
JOP20200118A1
JOP20200118A1 JOP/2020/0118A JOP20200118A JOP20200118A1 JO P20200118 A1 JOP20200118 A1 JO P20200118A1 JO P20200118 A JOP20200118 A JO P20200118A JO P20200118 A1 JOP20200118 A1 JO P20200118A1
Authority
JO
Jordan
Prior art keywords
oxalate
secretagogue
derived
secretagogues
subject
Prior art date
Application number
JOP/2020/0118A
Other languages
English (en)
Inventor
akerman maria
Lindner Elisabeth
Cowley Helena
Cowley Aaron
Original Assignee
Oxthera Intellectual Property Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxthera Intellectual Property Ab filed Critical Oxthera Intellectual Property Ab
Publication of JOP20200118A1 publication Critical patent/JOP20200118A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0016—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with NAD or NADP as acceptor (1.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1014—Hydroxymethyl-, formyl-transferases (2.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/0106—2-Hydroxy-3-oxopropionate reductase (1.1.1.60)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/01—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with NAD+ or NADP+ as acceptor (1.4.1)
    • C12Y104/01016—Diaminopimelate dehydrogenase (1.4.1.16)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/02—Hydroxymethyl-, formyl- and related transferases (2.1.2)
    • C12Y201/02001—Glycine hydroxymethyltransferase (2.1.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01006—Methionine adenosyltransferase (2.5.1.6), i.e. adenosylmethionine synthetase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01009—Riboflavin synthase (2.5.1.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01047—Cysteine synthase (2.5.1.47)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y303/00—Hydrolases acting on ether bonds (3.3)
    • C12Y303/01—Thioether and trialkylsulfonium hydrolases (3.3.1)
    • C12Y303/01001—Adenosylhomocysteinase (3.3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01003—Aconitate hydratase (4.2.1.3)

Abstract

يتعلق هذا الاختراع بمركب معزز الإفراز المشتق من بكتريا تكسير الأوكسالات، للاستخدام في علاج المرض المتعلق بالأوكسالات و/أو اختلال التوازن المتعلق بالأوكسالات في الفرد، حيث يتسبب إعطاء معزز الإفراز في اختزال الأوكسالات في البول و/أو أوكسالات البلازما في الفرد. يتعلق هذا الاختراع لتركيبة صيدلانية تتضمن مثل مركب معزز الإفراز، طريقة لعلاج الفرد الذي يعاني من المرض المتعلق بالأوكسالات، وطريقة لتحضير معزز الإفراز.
JOP/2020/0118A 2013-07-05 2013-07-05 مدرات الافراز مشتقة من اوكسالوباكتير فورميجينيس JOP20200118A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SE2013/050875 WO2015002588A1 (en) 2013-07-05 2013-07-05 Secretagogues derived from oxalobacter formigenes

Publications (1)

Publication Number Publication Date
JOP20200118A1 true JOP20200118A1 (ar) 2017-06-16

Family

ID=48856920

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2020/0118A JOP20200118A1 (ar) 2013-07-05 2013-07-05 مدرات الافراز مشتقة من اوكسالوباكتير فورميجينيس
JOP/2014/0212A JO3591B1 (ar) 2013-07-05 2014-07-03 مدرات الافراز مشتقة من اوكسالوباكتير فورميجينيس

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2014/0212A JO3591B1 (ar) 2013-07-05 2014-07-03 مدرات الافراز مشتقة من اوكسالوباكتير فورميجينيس

Country Status (7)

Country Link
US (3) US10125176B2 (ar)
EP (2) EP3865148A1 (ar)
CN (1) CN105358172B (ar)
DK (1) DK3016669T3 (ar)
ES (1) ES2869911T3 (ar)
JO (2) JOP20200118A1 (ar)
WO (2) WO2015002588A1 (ar)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015002588A1 (en) 2013-07-05 2015-01-08 Oxthera Intellectual Property Ab Secretagogues derived from oxalobacter formigenes
US20170035800A1 (en) * 2015-08-06 2017-02-09 Kenneth Davin Fine Reduction of Oxalate Absorption in Individuals
AU2017376780A1 (en) 2016-12-15 2019-07-04 Novome Biotechnologies, Inc. Compositions and methods for modulating growth of a genetically modified gut bacterial cell
WO2019169441A1 (en) * 2018-03-06 2019-09-12 Environmental Engineers International Pty Ltd Method for remediating industrial wastewater
WO2020018799A1 (en) 2018-07-18 2020-01-23 The University Of Chicago Compositions comprising sel1-derived peptides and methods of treatment/prevention of excess oxalate levels and associated conditions/diseases therewith
EP3860628A4 (en) * 2018-10-04 2022-08-17 OxThera Intellectual Property AB NEW MEDICAL USE OF OXALATE-REDUCING BACTERIA
CN109402022A (zh) * 2018-12-05 2019-03-01 上海上药信谊药厂有限公司 一种产甲酸草酸杆菌及其应用
RU2704022C1 (ru) * 2019-01-09 2019-10-23 Федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ протеомной коррекции оксалатного нефролитиаза

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69841200D1 (de) 1997-05-23 2009-11-12 Oxthera Inc Oxalate-abbauende mikroorganismen oder oxalate-abbauende enzyme zur verhütung der oxalate-verwandten krankheiten
US6355242B1 (en) 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
US8486389B2 (en) * 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
WO2005097176A2 (en) * 2004-03-26 2005-10-20 University Of Florida Research Foundation, Inc. Modulating oxalate transport
US20050232901A1 (en) * 2004-04-14 2005-10-20 Zaghmout Ousama M Materials and methods for treating or preventing oxalate-related disease
AU2005339139A1 (en) 2005-12-14 2007-06-21 Oxthera, Inc. Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
EP2046373B1 (en) * 2006-08-02 2013-03-20 Althea Technologies, Inc. Crystallized oxalate decarboxylase and methods of use
US20130333068A1 (en) * 2008-04-29 2013-12-12 Marie Coffin Genes and uses for plant enhancement
WO2015002588A1 (en) 2013-07-05 2015-01-08 Oxthera Intellectual Property Ab Secretagogues derived from oxalobacter formigenes

Also Published As

Publication number Publication date
WO2015002604A1 (en) 2015-01-08
US20190085035A1 (en) 2019-03-21
US20160137701A1 (en) 2016-05-19
JO3591B1 (ar) 2020-07-05
US20220098247A1 (en) 2022-03-31
WO2015002588A1 (en) 2015-01-08
EP3016669A1 (en) 2016-05-11
CN105358172B (zh) 2019-12-10
DK3016669T3 (da) 2021-05-10
US10125176B2 (en) 2018-11-13
EP3865148A1 (en) 2021-08-18
US10988510B2 (en) 2021-04-27
CN105358172A (zh) 2016-02-24
ES2869911T3 (es) 2021-10-26
EP3016669B8 (en) 2021-04-21
EP3016669B1 (en) 2021-03-31

Similar Documents

Publication Publication Date Title
JO3591B1 (ar) مدرات الافراز مشتقة من اوكسالوباكتير فورميجينيس
PH12016501750A1 (en) Human plasma kallikrein inhibitors
MY192088A (en) Combinantion therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2019010601A (es) Terapia de combinacion para tratar cancer.
GB201209609D0 (en) New compounds
MX2016007351A (es) Terapia de combinacion para tratar cancer.
SG10201903119QA (en) Polypeptide vaccine
GB201118656D0 (en) New compounds
GB201304501D0 (en) Liquid pharmaceutical compositions
MX2015010829A (es) Compuestos terapeuticos y sus usos.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX349948B (es) Proteínas inmunógenas y composiciones para el tratamiento y prevención de streptococcus agalactiae.
IN2013MU03583A (ar)
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
MX358512B (es) Uso de (r)-7cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma para preparar una composición farmacéutica en el tratamiento de una disfunción cognitiva.
GB201114923D0 (en) Immunogenic proteins and compositions
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
MX2016003763A (es) Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple.